SURESH CHINTALAPATI

Dr Chintalapati is the Founder of Triangulum Biopharmaand has been serving as the President and Chief Business Officer since 2016. Dr Suresh Chintalapati is also the founder of Mabgenex, an antibody and peptide discovery company, where he has been serving as the CEO and Chairman since 2018.

Prior to Triangulum, Dr Chintalapati was a Partner and served on the board as Chief Strategic Adviser for GenomeSense, a Global Molecular Diagnostics Institute. Dr Chintalapati held various Commercial and Business Development positions at Sanford Burnham Prebys Medical Discovery Institute, Illumina and Pathway Genomics.

Dr Chintalapati is an accomplished scientist with 15 years of research experience in Molecular Biology and Immunology, with over a dozen peer reviewed publications. Dr Chintalapati's post doctoral research was at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. Dr Chintalapati has an MS in Biotechnology from University of Hyderabad, PhD in Molecular Biology from Center for Cellular and Molecular Biology (CCMB) and an MBA.

At Triangulum Biopharma, having directly worked on drug discovery and development, we understand the dynamics of the process. We understand what is needed, how fast it is needed, and how to help design the studies to obtain rapid and clear answers to our clients.